59.61
-1.48 (-2.42%)
| Previous Close | 61.09 |
| Open | 61.08 |
| Volume | 1,464,051 |
| Avg. Volume (3M) | 1,383,748 |
| Market Cap | 7,584,001,536 |
| Price / Earnings (TTM) | 19.74 |
| Price / Earnings (Forward) | 10.91 |
| Price / Sales | 6.52 |
| Price / Book | 13.36 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 |
| Profit Margin | 41.43% |
| Operating Margin (TTM) | 56.26% |
| Diluted EPS (TTM) | 3.02 |
| Quarterly Revenue Growth (YOY) | 34.30% |
| Quarterly Earnings Growth (YOY) | 67.40% |
| Total Debt/Equity (MRQ) | 339.05% |
| Current Ratio (MRQ) | 10.36 |
| Operating Cash Flow (TTM) | 402.95 M |
| Levered Free Cash Flow (TTM) | 339.29 M |
| Return on Assets (TTM) | 14.87% |
| Return on Equity (TTM) | 111.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Halozyme Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 100.80% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 73.00 (JMP Securities, 22.46%) | Buy |
| Median | 63.50 (6.53%) | |
| Low | 53.00 (Piper Sandler, -11.09%) | Hold |
| Average | 63.25 (6.11%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 54.22 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 13 Jan 2025 | 57.00 (-4.38%) | Hold | 54.14 |
| HC Wainwright & Co. | 10 Jan 2025 | 70.00 (17.43%) | Buy | 52.80 |
| 30 Dec 2024 | 68.00 (14.07%) | Buy | 47.99 | |
| Piper Sandler | 10 Jan 2025 | 53.00 (-11.09%) | Hold | 52.80 |
| 04 Nov 2024 | 52.00 (-12.77%) | Hold | 58.47 | |
| JMP Securities | 01 Nov 2024 | 73.00 (22.46%) | Buy | 57.15 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |